VC
CRBP icon

Vivo Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Vivo Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-166,794
Closed -$1.97M – 41
2024
Q4 		$1.97M Hold
166,794
– – 0.22% 35
2024
Q3 		$3.44M Hold
166,794
– – 0.28% 34
2024
Q2 		$7.55M Buy
+166,794
New +$7.02M 0.7% 27

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vivo Capital's CRBP Position: Q1 2025 in Review

Vivo Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 166,794 shares — an estimated $1.97M sold.

Vivo Capital first reported a position in CRBP in Q2 2024 and held it in 3 quarters. The position peaked at $7.55M in Q2 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Vivo Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Vivo Capital sold 166,794 Corbus Pharmaceuticals shares in Q1 2025, an estimated $1.97M.
  • Vivo Capital first reported a position in Corbus Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Vivo Capital's Corbus Pharmaceuticals position peaked at $7.55M in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Vivo Capital's 13F filing for Q1 2025, filed 12 May 2025.